![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | C07K 16/18 | (2006.01) |
G01N 33/577 | (2006.01) | ||
A61K 39/395 | (2006.01) | ||
A61P 25/28 | (2006.01) |
(11) | Number of the document | 2603523 |
(13) | Kind of document | T |
(96) | European patent application number | 11745672.3 |
Date of filing the European patent application | 2011-08-09 | |
(97) | Date of publication of the European application | 2013-06-19 |
(45) | Date of publication and mention of the grant of the patent | 2016-01-27 |
(46) | Date of publication of the claims translation | 2016-04-11 |
(86) | Number | PCT/US2011/046994 |
Date | 2011-08-09 |
(87) | Number | WO 2012/021469 |
Date | 2012-02-16 |
(30) | Number | Date | Country code |
373026 P | 2010-08-12 | US |
(72) |
LU, Jirong, US
TANG, Ying, US
DEMATTOS, Ronald Bradley, US
|
(73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
(74) |
Jelena GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
(54) | Anti-N3pGlu amiloido beta peptido antikūnai ir jų panaudojimas |
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Payment date | Validity (years) | Amount | |
2025-07-23 | 15 | 289.00 EUR |
2026-08-09 |